Complications of intragastric balloons
The American Society for Gastrointestinal Endoscopy (ASGE) and the American Society for Metabolic and Bariatric Surgery (ASMBS) have defined acceptable thresholds of safety and efficacy for primary endoscopic bariatric therapies (EBTs). Specifically, a given EBT should have an incidence of serious adverse events ≤5% and should result in ≥25% excessive weight loss (EWL) at 12 months, and this EWL should be ≥15% higher than in a control group. In recent decades, several intragastric balloons (IGBs) have demonstrated safety and efficacy, with broad adoption internationally. The U.S.